{"nctId":"NCT03110380","briefTitle":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed","startDateStruct":{"date":"2017-06-12","type":"ACTUAL"},"conditions":["HIV-1-infection"],"count":567,"armGroups":[{"label":"B/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF","Drug: DTG Placebo","Drug: F/TAF Placebo"]},{"label":"DTG + F/TAF","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: F/TAF","Drug: DTG","Drug: B/F/TAF Placebo"]},{"label":"Open-label Phase B/F/TAF from B/F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF"]},{"label":"Open-label Phase B/F/TAF from DTG + F/TAF","type":"EXPERIMENTAL","interventionNames":["Drug: B/F/TAF"]}],"interventions":[{"name":"B/F/TAF","otherNames":["GS-9883/F/TAF","Biktarvy®"]},{"name":"F/TAF","otherNames":["Descovy®"]},{"name":"DTG","otherNames":["Tivicay®"]},{"name":"DTG Placebo","otherNames":[]},{"name":"F/TAF Placebo","otherNames":[]},{"name":"B/F/TAF Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:\n\n  * ≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance prior to the screening visit)\n  * ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit)\n* Documented plasma HIV-1 ribonucleic acid (RNA) \\< 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the screening visit\n* Plasma HIV-1 RNA levels \\< 50 copies/mL at screening visit\n* Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance\n* No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed virologic failure\n* Eligible adults with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection are permitted to enroll\n\nNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","description":"The percentage of participants achieving HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"91.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4+ Cell Count at Week 48","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":"179.1"},{"groupId":"OG001","value":"36","spread":"152.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":284},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Arthralgia","Headache"]}}}